Researchers have developed a new oral medication called Lipfendra (enlicitide), which has been approved by the U.S. Food and Drug Administration (FDA) as the first oral PCSK9 inhibitor. This innovative drug offers a convenient alternative for people struggling to lower their LDL cholesterol levels, often referred to as “bad” cholesterol, which is a major risk factor for cardiovascular diseases like heart attacks and strokes. Lipfendra can significantly reduce LDL cholesterol levels by an average of 56% to 59% when added to existing treatments.

For individuals looking to age well, managing LDL cholesterol is crucial. High levels of LDL can lead to plaque buildup in arteries, increasing the risk of serious cardiovascular events. Lipfendra is particularly beneficial for adults who have high cholesterol despite taking the maximum tolerated dose of statins or for those who cannot tolerate statins at all. Notably, about 45% of participants in the clinical trials for Lipfendra were aged 65 or older, showing that it can be a viable option for older adults concerned about heart health.

The evidence for Lipfendra comes from two large Phase 3 clinical trials involving over 3,200 adults. While these trials demonstrated its effectiveness in lowering LDL cholesterol, it is important to note that the drug’s ability to prevent heart attacks and strokes is still being investigated in an ongoing study. Until those results are available, Lipfendra should be viewed as a complementary treatment rather than a replacement for statins, which remain the cornerstone of cholesterol management.

If you’re considering options for managing your cholesterol, talk to your healthcare provider about whether Lipfendra might be appropriate for you. Remember, medication is just one piece of the puzzle; maintaining a healthy lifestyle through diet, exercise, and regular check-ups is essential for long-term cardiovascular health.

Source: superagingnews.com